XBIO Xenetic Bio Company Cash Volume

Symbol and logo of brand xeneticbio.com (XBIO)

The growth of Xenetic Biosciences (XBIO) is based on the success of the DNase platform and clinical milestones, while demand for oncology therapy remains independent of economic cycles. The cash position illustrates financial stability, and this parameter has stabilized at 0.01. The company is currently focusing on its own pipeline, limiting partnerships solely to joint combination therapy trials.

Xenetic Biosciences - XBIO Company Cash Balance (period 07/04/2022 - 11/21/2026)

Analytical breakdowns and data insights for company xeneticbio.com (XBIO)

- stock quotes and analyst forecast:
Analysis of all company metrics:XBIO xeneticbio.com
Brand item of Xenetic Biosciences

Fundamental asset selection is based on liquidity analysis to assess business autonomy. This indicator measures the volume of internal funds, determining the company's ability to operate without external borrowing. For Xenetic Biosciences (XBIO), this resource is critical, as it ensures the independence of R&D processes and the retention of leading oncologists through RSU programs. The trend in cash on hand reflects the efficiency of capital management. By analyzing cash on hand, an investor identifies the balance between financial stability and the risk of inefficient resource allocation.

Main competitors

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|PSNL - Company Liquid Assets|ERAS (Erasca Inc) - Company Cash Volume|Company Cash Reserve Delcath Systems Inc DCTH|Company Cash Funds YmAbs (YMAB)|Company Liquid Assets Aura Bio|Company Cash Volume CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Company Cash Reserve|SELLAS Life Sciences Group - Company Cash Volume|ACTU - Company Cash Volume|CTOR: Company Cash Volume|Company Cash Reserve TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Company Cash Volume|Fate Therapeutics, Inc. (FATE) - Company Liquid Assets|Company Cash on Hand WHWK (Aadi Bioscience, Inc.)|Company Liquid Assets TScan Therapeutics, Inc.|Company Cash Volume CSBR (Champions Oncology Corp)|Company Total Cash Amount XBIT (XBiotech USA)|CVM - Company Cash Funds|Company Cash Balance OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Company Cash Funds|ARTV: Company Total Cash Amount|ANL (adlainortye.com) - Company Cash Volume|VERU: Company Cash Balance|Company Cash on Hand TPST (Tempest Tx)|Company Cash on Hand Xilio XLO|Company Cash Volume RENB (Renovaro)|Company Cash Volume Mural Bio MURA|Kairos Pharma Ltd - Company Cash Volume|OnKure Therapeutics (OKUR) - Company Cash on Hand|GDTC: Company Cash Volume|Curis Inc. - Company Cash Balance|Company Cash Funds apollomicsinc.com|THAR: Company Cash Balance|Company Cash Funds Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Company Cash Balance|Company Cash Volume CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Company Cash Reserve|SLRX: Company Cash on Hand|Company Cash Balance PPBT (Purple Biotech Ltd.)|AONC: Company Cash Volume|Company Cash Reserve BeOne Medicines (BGNE)|Company Cash Funds Checkpoint Therapeutics, Inc.|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds